Fox Run Management L.L.C. Invests $265,000 in Enfusion, Inc. (NYSE:ENFN)

Fox Run Management L.L.C. bought a new stake in Enfusion, Inc. (NYSE:ENFN) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 25,736 shares of the company’s stock, valued at approximately $265,000.

Other institutional investors have also recently bought and sold shares of the company. Centiva Capital LP grew its stake in shares of Enfusion by 5.0% during the 3rd quarter. Centiva Capital LP now owns 25,596 shares of the company’s stock worth $243,000 after acquiring an additional 1,227 shares in the last quarter. Rhumbline Advisers grew its position in Enfusion by 3.0% in the fourth quarter. Rhumbline Advisers now owns 62,464 shares of the company’s stock valued at $643,000 after purchasing an additional 1,796 shares in the last quarter. Azora Capital LP increased its stake in Enfusion by 6.8% in the 3rd quarter. Azora Capital LP now owns 29,827 shares of the company’s stock valued at $283,000 after buying an additional 1,890 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Enfusion by 3.3% in the 4th quarter. Bank of New York Mellon Corp now owns 126,541 shares of the company’s stock valued at $1,303,000 after buying an additional 4,032 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Enfusion by 1.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 371,151 shares of the company’s stock worth $3,823,000 after buying an additional 5,639 shares in the last quarter. Institutional investors own 81.05% of the company’s stock.

Insiders Place Their Bets

In other news, insider Bronwen Bastone sold 3,126 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $11.38, for a total transaction of $35,573.88. Following the completion of the sale, the insider now owns 221,875 shares in the company, valued at $2,524,937.50. The trade was a 1.39 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Neal Pawar sold 2,769 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $11.48, for a total value of $31,788.12. Following the completion of the transaction, the chief operating officer now directly owns 1,231,627 shares in the company, valued at $14,139,077.96. The trade was a 0.22 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 77,346 shares of company stock valued at $868,109 over the last ninety days. 36.44% of the stock is currently owned by company insiders.

Enfusion Stock Performance

Shares of ENFN stock opened at $11.15 on Friday. Enfusion, Inc. has a 52-week low of $7.83 and a 52-week high of $11.80. The stock has a market cap of $1.44 billion, a price-to-earnings ratio of 278.69, a PEG ratio of 1.85 and a beta of 0.95. The firm’s 50-day moving average is $11.18 and its 200-day moving average is $10.16.

Enfusion (NYSE:ENFN) last released its quarterly earnings data on Monday, March 3rd. The company reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). The business had revenue of $52.94 million during the quarter, compared to analyst estimates of $53.98 million. Enfusion had a net margin of 1.70% and a return on equity of 6.67%. Sell-side analysts predict that Enfusion, Inc. will post 0.06 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on ENFN. Stifel Nicolaus raised their price objective on Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. William Blair reaffirmed a “market perform” rating on shares of Enfusion in a research report on Monday, January 13th. Finally, Piper Sandler upped their price objective on Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a research note on Monday, December 23rd.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.